GlassScriptPhysician profile
Deven Willardson
NPI 1376033456
$9,979.56
in general payments reported to CMS, 2019-2025
12 companies · $3,670 in 2025
The $3,670 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $203 · 2022: $3,445 · 2023: $729 · 2024: $1,934 · 2025: $3,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,424 · Consulting Fee: $1,805 · Travel and Lodging: $1,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.36 |
| Consulting Fee | $1,805.00 |
| Travel and Lodging | $1,102.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $3,903.10 | 2022-2025 | Nalu Neurostimulation System |
| Abbott Laboratories | $2,618.41 | 2021-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $1,940.24 | 2021-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Abbvie INC. | $664.67 | 2021-2025 | |
| Medtronic, INC. | $641.34 | 2022-2025 | Synchromedii, Inceptiv, Intellis Adaptivestim |
| Nevro Corp. | $86.56 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $37.59 | 2025 | Ajovy |
| Pfizer INC. | $27.05 | 2024 | |
| Scilex Pharmaceuticals INC. | $18.54 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.81 | 2024 | |
| Merz Pharmaceuticals, LLC | $13.36 | 2024 | Xeomin |
| Biohaven Pharmaceutical Holding Company LTD. | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deven Willardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.